- Email: [email protected]
Contents, Author and Keyword Indices
DRUG RESISTANCE
Updates
Reviews and commentaries in antimicrobial and anticancer chemotheraphy
Volume 7, 2004 List of Contents, Author, and Keyword Indices
doi:10.1016/S1368-7646(05)00017-8
DRUG RESISTANCE
Updates
Reviews and commentaries in antimicrobial and anticancer chemotherapy
Editor-in-chief Nafsika Georgopapadakou
Bacteria Section Editor Nafsika Georgopapadakou Department of Microbiology and Immunology Temple University School of Medicine Philadelphia, Pennsylvania, USA
Cancer Section Editor Henk J Broxterman Dept of Medical Oncology, BR 232 Free University Hospital Amsterdam, The Netherlands
Fungi Section Editor John R Perfect Duke University Durham North Carolina USA
Protozoa Section Editor Steve A Ward Liverpool School of Tropical Medicine, University of Liverpool Liverpool, UK
Viruses Section Editor Eric J Arts Department of Medicine Case Western Reserve University Cleveland, Ohio, USA
Editorial Board G L Archer, USA F Baquero, Spain H F Chambers, USA P Courvalin, France E Cundliffe, UK R E W Hancock, Canada K Hiramatsu, Japan D Hooper, USA G A Jacoby Jr, USA B Kreiswirth, USA
S A Lerner, USA S Levy, USA R Moellering, USA B Murray, USA H Nikaido, USA L Peterson, USA B Rosen, USA M Sande, USA B Spratt, UK R A Skurray, Australia B Wiedemann, Germany
Editorial Board S Ackland, Australia W T Beck, USA J R Bertino, USA P Borst, The Netherlands P A Bunn, USA C Cass, Canada P Dennis USA P J Houghton, USA M B Kastan, USA S B Kaye, UK
V Ling, Canada H M Pinedo, The Netherlands Y G Pommier, USA I Roninson, USA A Sparreboom, USA B A Teicher, USA K D Tew, USA T Tsuruo, Japan E G E de Vries, The Netherlands C R Wolf, UK
Editorial Board S L Kelly, UK J Kovacs, USA J Rex, UK
D Sanglard, Switzerland T Walsh, USA D Warnock, USA
Editorial Board Alan F Cowman, Australia P J Johnson, USA M Ouellette, Canada
T Wellems, USA N J White, Thailand
Editorial Board D M Coen, USA E D A DeClerq, Belgium F G Hayden, USA D R Kuritzkes, USA
J Montaner, Canada D Richman, USA M A Wainberg, Canada
CONTENTS OF VOLUME 7 Number 1 Editorial
1
Mini reviews Immunotherapy for invasive fungal infections: from bench to bedside Peter G. Pappas
3
Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Rolf Jakobi
11
Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Marion S. Freistadt, Glen D. Meades, Craig E. Cameron
19
Reviews Targeting hypoxia tolerance in cancer Bradly G. Wouters, Twan van den Beucken, Michael G. Magagnin, Philippe Lambin, Costas Koumenis
25
Opportunistic amoebae: challenges in prophylaxis and treatment Frederick L. Schuster, Govinda S. Visvesvara
41
NF-kB in cancer—a friend turned foe Rajani Ravi, Atul Bedi
53
Literature highlights Recent research in infectious disease drug resistance
69
Meetings calendar
75
Number 2 Perspectives New cancer therapeutics: target-specific in, cytotoxics out? Henk J. Broxterman, Nafsika H. Georgopapadakou
79
Minireview HIV resistance to the fusion inhibitor enfuvirtide:mechanisms and clinical implications Michael D. Miller, Daria J. Hazuda
89
Reviews ROS stress in cancer cells and therapeutic implications Helene Pelicano, Dennis Carney, Peng Huang
97
Evolution of the serine b-lactamases: past, present and future Barry G. Hall, Miriam Barlow
111
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Martin E. Eichhorn, Sebastian Strieth, Marc Dellian
125
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Sharmila Shankar, Rakesh K. Srivastava
139
Literature highlights Recent research in infectious disease drug resistance
157
Meetings calendar
159
Number 3 Perspectives The emergence of HIV resistance and new antiretrovirals: are we winning? Mark A. Wainberg
163
Reviews Multifaceted roles of cyclooxygenase-2 in lung cancer Karen Riedl, Kostyantyn Krysan, Mehis Po˜ld, Harnisha Dalwadi, Nathalie Heuze-Vourc’h, Mariam Dohadwala, Ming Liu, Xiaoyan Cui, Robert Figlin, Jenny T. Mao, Robert Strieter, Sherven Sharma, Steven M. Dubinett
169
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance David Andes
185
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases ¨ rgen Venitz, William D. Figg, Alex Sparreboom Milin R. Acharya, Ju
195
Customizing chemotherapy for colon cancer: the potential of gene expression profiling John M. Mariadason, Diego Arango, Leonard H. Augenlicht
209
Literature highlights Recent research in infectious disease drug resistance
219
Meetings calendar
223
Numbers 4–5 Minireview Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Roman P. Wernyj, Patrice J. Morin
227
Reviews Artemisinins: mechanisms of action and potential for resistance Sanjeev Krishna, Anne-Catrin Uhlemann, Richard K. Haynes
233
Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Moulay A. Alaoui-Jamali, Isabelle Dupre´, He Qiang
245
Leishmaniasis: drugs in the clinic, resistance and new developments Marc Ouellette, Jolyne Drummelsmith, Barbara Papadopoulou
257
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Jens M. Teodoridis, Gordon Strathdee, Robert Brown
267
Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Miriam K. Laufer, Christopher V. Plowe
279
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Julia Glade Bender, Erin M. Cooney, Jessica J. Kandel, Darrell J. Yamashiro
289
Candida biofilm resistance Pranab K. Mukherjee, Jyotsna Chandra
301
Literature highlights Literature highlights: recent research in infectious diseases drug resistance
311
Meetings calendar
317
Number 6 Perspective Cancer cell death by programmed necrosis? Piet Borst, Sven Rottenberg
321
Minireview Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Lajos Pusztai, Roman Rouzier, Peter Wagner, W. Fraser Symmans
325
Reviews Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Shazib Pervaiz
333
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Caroline M.M. Van Geelen, Elisabeth G.E. de Vries, Steven de Jong
345
Literature highlights Recent research in infectious disease drug resistance
359
Meetings calendar
367
Volume Contents, Author & Keyword Indices, Volume 7 2004
I
Drug Resistance Updates 7 (2004) VII
AUTHOR INDEX VOLUME 7 Acharya, M.R. 195 Alaoui-Jamali, M.A. 245 Andes, D. 185 Arango, D. 209 Arts, E. 1 Augenlicht, L.H. 209 Barlow, M. 111 Bedi, A. 53 Borst, P. 321 Brown, R. 267 Broxterman, H. 1 Broxterman, H.J. 79 Cameron, C.E. 19 Carney, D. 97 Chandra, J. 301 Cooney, E.M. 289 Cui, X. 169 Dalwadi, H. 169 de Jong, S. 345 de Vries, E.G.E. 345 Dellian, M. 125 Dohadwala, M. 169 Drummelsmith, J. 257 Dubinett, S.M. 169 Dupre´, I. 245
Georgopapadakou, N.H. 79 Glade Bender, J. 289
Po˜ ld, M. 169 Pusztai, L. 325
Hall, B.G. 111 Haynes, R.K. 233 Hazuda, D.J. 89 Heuze-Vourc’h, N. 169 Huang, P. 97
Qiang, H. 245 Ravi, R. 53 Riedl, K. 169 Rottenberg, S. 321 Rouzier, R. 325
Jakobi, R. 11 Kandel, J.J. 289 Koumenis, C. 25 Krishna, S. 233 Krysan, K. 169 Lambin, P. 25 Laufer, M.K. 279 Liu, M. 169 Magagnin, M.G. 25 Mao, J.T. 169 Mariadason, J.M. 209 Meades, G.D. 19 Miller, M.D. 89 Morin, P.J. 227 Mukherjee, P.K. 301
Schuster, F.L. 41 Shankar, S. 139 Sharma, S. 169 Sparreboom, A. 195 Srivastava, R.K. 139 Strathdee, G. 267 Strieter, R. 169 Strieth, S. 125 Symmans, W.F. 325 Teodoridis, J.M. 267 Uhlemann, A.-C. 233 van den Beucken, T. 25 Van Geelen, C.M.M. 345 Venitz, J. 195 Visvesvara, G.S. 41
Ouellette, M. 257 Eichhorn, M.E. 125 Figg, W.D. 195 Figlin, R. 169 Freistadt, M.S. 19 Georgopapadakou, N. 1
Papadopoulou, B. 257 Pappas, P.G. 3 Pelicano, H. 97 Perfect, J. 1 Pervaiz, S. 333 Plowe, C.V. 279
Wagner, P. 325 Wainberg, M.A. 163 Ward, S. 1 Wernyj, R.P. 227 Wouters, B.G. 25 Yamashiro, D.J. 289
Drug Resistance Updates 7 (2004) IX–XV
KEYWORD INDEX VOLUME 7 ABC transporters Leishmaniasis: drugs in the clinic, resistance and new developments Acanthamoeba spp. Opportunistic amoebae: challenges in prophylaxis and treatment Adjuvant chemotherapy Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? AEE788 New cancer therapeutics: target-specific in, cytotoxics out? Alkylating agents Cancer cell death by programmed necrosis? Amoebic encephalitis Opportunistic amoebae: challenges in prophylaxis and treatment Amoebic keratitis Opportunistic amoebae: challenges in prophylaxis and treatment Amphotericin B Leishmaniasis: drugs in the clinic, resistance and new developments Amphotericin pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Angiogenesis Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Angiopoietin Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Anti-angiogenesis Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Anti-angiogenic therapy Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Anticancer agents ROS stress in cancer cells and therapeutic implications Anticancer drugs Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Antifungal PK/PD Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Antifungal therapy Candida biofilm resistance Antiviral agent Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Apoptosis Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis NF-kB in cancer—a friend turned foe ROS stress in cancer cells and therapeutic implications Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Cancer cell death by programmed necrosis? Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Artemisinin Artemisinins: mechanisms of action and potential for resistance Balamuthia mandrillaris Opportunistic amoebae: challenges in prophylaxis and treatment
257 41 325 79 321 41 41 257 185 125 289 125 289 125 97 195 185 301 19 11 53 97 139 321 345 233
41
X
KEYWORD INDEX VOLUME 7
Bevacizumab Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Biofilm Candida biofilm resistance Biomarkers New cancer therapeutics: target-specific in, cytotoxics out? BMS-488043 The emergence of HIV resistance and new antiretrovirals: are we winning? Breast cancer Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Cancer NF-kB in cancer—a friend turned foe ROS stress in cancer cells and therapeutic implications Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Cancer chemoprevention Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Cancer therapy Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Carcinogenesis NF-kB in cancer—a friend turned foe Caspase Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Caspase-activated protein kinases Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Celecoxib Multifaceted roles of cyclooxygenase-2 in lung cancer Chemically modified tetracyclines Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Chloroquine Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies CI-1040 New cancer therapeutics: target-specific in, cytotoxics out? Cisplatin Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel CK2 NF-kB in cancer—a friend turned foe Clinical trial Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Multifaceted roles of cyclooxygenase-2 in lung cancer Colon cancer Customizing chemotherapy for colon cancer: the potential of gene expression profiling Colon carcinoma Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Coxsackievirus B3 Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? CpG-islands Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Cyclooxygenase Multifaceted roles of cyclooxygenase-2 in lung cancer Cytokine growth factors Immunotherapy for invasive fungal infections: from bench to bedside DcR1 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy DcR2 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Death receptor Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
289 301 79 163 325
53 97 245 333 11 53
139 11 169 195 279 79 227 53 125 169 209 345 19 267 169 3
345 345
139
KEYWORD INDEX VOLUME 7
Dihydrofolate reductase Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Dihydropteroate synthase Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies DNMT Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker DR4 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy DR5 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug development Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Drug resistance Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Drug susceptibility Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Drug-resistant HIV The emergence of HIV resistance and new antiretrovirals: are we winning? Echinocandin pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Endoperoxides Artemisinins: mechanisms of action and potential for resistance Enfuvirtide HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Entry HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Epigenetics Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Erlotinib New cancer therapeutics: target-specific in, cytotoxics out? Error catastrophe Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Evolutionary potential Evolution of the serine b-lactamases: past, present and future Flavonoids Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Fluconazole Leishmaniasis: drugs in the clinic, resistance and new developments Fluconazole pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance 5-FU Customizing chemotherapy for colon cancer: the potential of gene expression profiling Fusion HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Gefitinib New cancer therapeutics: target-specific in, cytotoxics out? Gene expression profiling Customizing chemotherapy for colon cancer: the potential of gene expression profiling Genomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Gleevec New cancer therapeutics: target-specific in, cytotoxics out? Glucantime Leishmaniasis: drugs in the clinic, resistance and new developments Glycolysis Cancer cell death by programmed necrosis?
XI
279 279 267 345 345 195 185 227 245 279 245 163
185 233 89 89 267 79 19 111 333 257 185 209 89
79 209 245 79 257 321
XII
KEYWORD INDEX VOLUME 7
Gp120 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Gp41 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Granulocyte infusions Immunotherapy for invasive fungal infections: from bench to bedside GW678248 The emergence of HIV resistance and new antiretrovirals: are we winning? GW873140 The emergence of HIV resistance and new antiretrovirals: are we winning? Hepatitis C virus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? HIF Targeting hypoxia tolerance in cancer Histones Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker HIV HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications HIV protease The emergence of HIV resistance and new antiretrovirals: are we winning? Hypoxia Targeting hypoxia tolerance in cancer Hypoxia tolerance Targeting hypoxia tolerance in cancer IAP Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications IKK NF-kB in cancer—a friend turned foe Imatinib New cancer therapeutics: target-specific in, cytotoxics out? Immunotherapy Immunotherapy for invasive fungal infections: from bench to bedside Intensive Care Unit Candida biofilm resistance Invasive fungal infections Immunotherapy for invasive fungal infections: from bench to bedside Iressa New cancer therapeutics: target-specific in, cytotoxics out? Kala azar Leishmaniasis: drugs in the clinic, resistance and new developments b-Lactamases Evolution of the serine b-lactamases: past, present and future Leishmania Leishmaniasis: drugs in the clinic, resistance and new developments Leishmaniasis Leishmaniasis: drugs in the clinic, resistance and new developments Lethal mutagenesis Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Lung cancer Multifaceted roles of cyclooxygenase-2 in lung cancer Malaria Artemisinins: mechanisms of action and potential for resistance Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Matrix metalloproteinase Chemically modified tetracyclines as inhibitors of matrix metalloproteinases
89 89 3 163 163
19 25 267 89 163 25 25
139 53 79 3 301 3 79
257
111 257 257 19 169
233 279 195
KEYWORD INDEX VOLUME 7
Meglumine antimoniate Leishmaniasis: drugs in the clinic, resistance and new developments Methylation Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Microarray Customizing chemotherapy for colon cancer: the potential of gene expression profiling Miltefosine Leishmaniasis: drugs in the clinic, resistance and new developments Mitochondria ROS stress in cancer cells and therapeutic implications Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Molecular targets Targeting hypoxia tolerance in cancer Mother-to-child transmission The emergence of HIV resistance and new antiretrovirals: are we winning? MUC1 Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel NAD+ Cancer cell death by programmed necrosis? NADP+ Cancer cell death by programmed necrosis? Naegleria fowleri Opportunistic amoebae: challenges in prophylaxis and treatment Necrosis Cancer cell death by programmed necrosis? NF-kB NF-kB in cancer—a friend turned foe NNRTIs The emergence of HIV resistance and new antiretrovirals: are we winning? NRTIs The emergence of HIV resistance and new antiretrovirals: are we winning? PARP Cancer cell death by programmed necrosis? PD0325901 New cancer therapeutics: target-specific in, cytotoxics out? PDGF Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Pentamidine Leishmaniasis: drugs in the clinic, resistance and new developments Pentavalent antimonials Leishmaniasis: drugs in the clinic, resistance and new developments Pentostam Leishmaniasis: drugs in the clinic, resistance and new developments PfCRT Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Pharmacogenomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? (Phospho)proteomics New cancer therapeutics: target-specific in, cytotoxics out? Phylogenies Evolution of the serine b-lactamases: past, present and future Plasmodium falciparum Artemisinins: mechanisms of action and potential for resistance Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Platinum compounds Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Poliovirus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance?
XIII
257 267 209 257 97 139 25 163 227
321 321 41 321 53 163 163
321 79 289 257 257 257 279 245 325 79 111 233 279 227 19
XIV
KEYWORD INDEX VOLUME 7
Predicting evolution Evolution of the serine b-lactamases: past, present and future Predictive markers Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Pro-inflammatory cytokines Immunotherapy for invasive fungal infections: from bench to bedside Protein kinase inhibitors New cancer therapeutics: target-specific in, cytotoxics out? Proteomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Reactive oxygen species (ROS) ROS stress in cancer cells and therapeutic implications Resistance HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Resistance mechanisms Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Resveratrol Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Reverse transcriptase The emergence of HIV resistance and new antiretrovirals: are we winning? Reverset The emergence of HIV resistance and new antiretrovirals: are we winning? Ribavirin Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? RNA virus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? RNA-dependent RNA polymerase Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Sappinia diploidea Opportunistic amoebae: challenges in prophylaxis and treatment SCH-D The emergence of HIV resistance and new antiretrovirals: are we winning? SPD754 The emergence of HIV resistance and new antiretrovirals: are we winning? Stibogluconate Leishmaniasis: drugs in the clinic, resistance and new developments SU-11248 New cancer therapeutics: target-specific in, cytotoxics out? SU-5416 New cancer therapeutics: target-specific in, cytotoxics out? Subcellular localization Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Sulfadoxine–pyrimethamine Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Tarceva New cancer therapeutics: target-specific in, cytotoxics out? Target selection New cancer therapeutics: target-specific in, cytotoxics out? Therapy Targeting hypoxia tolerance in cancer TMC114 The emergence of HIV resistance and new antiretrovirals: are we winning? TRAIL Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications TRAIL-resistance Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Translation Targeting hypoxia tolerance in cancer
111 325 3 79 245
97 89 227 333 163 163 19 19 19
41 163 163 257 79 79 11 279
79 79 25 163
139 345 25
KEYWORD INDEX VOLUME 7
Trastuzumab New cancer therapeutics: target-specific in, cytotoxics out? Treatment NF-kB in cancer—a friend turned foe Tumor Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Vascular remodeling Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Vascular targeting Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives VEGF Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Xyotax New cancer therapeutics: target-specific in, cytotoxics out? ZD1839 New cancer therapeutics: target-specific in, cytotoxics out? ZM447439 New cancer therapeutics: target-specific in, cytotoxics out?
XV
79 53 125
289 125 289
79
79 79
Updates
Reviews and commentaries in antimicrobial and anticancer chemotheraphy
Volume 7, 2004 List of Contents, Author, and Keyword Indices
doi:10.1016/S1368-7646(05)00017-8
DRUG RESISTANCE
Updates
Reviews and commentaries in antimicrobial and anticancer chemotherapy
Editor-in-chief Nafsika Georgopapadakou
Bacteria Section Editor Nafsika Georgopapadakou Department of Microbiology and Immunology Temple University School of Medicine Philadelphia, Pennsylvania, USA
Cancer Section Editor Henk J Broxterman Dept of Medical Oncology, BR 232 Free University Hospital Amsterdam, The Netherlands
Fungi Section Editor John R Perfect Duke University Durham North Carolina USA
Protozoa Section Editor Steve A Ward Liverpool School of Tropical Medicine, University of Liverpool Liverpool, UK
Viruses Section Editor Eric J Arts Department of Medicine Case Western Reserve University Cleveland, Ohio, USA
Editorial Board G L Archer, USA F Baquero, Spain H F Chambers, USA P Courvalin, France E Cundliffe, UK R E W Hancock, Canada K Hiramatsu, Japan D Hooper, USA G A Jacoby Jr, USA B Kreiswirth, USA
S A Lerner, USA S Levy, USA R Moellering, USA B Murray, USA H Nikaido, USA L Peterson, USA B Rosen, USA M Sande, USA B Spratt, UK R A Skurray, Australia B Wiedemann, Germany
Editorial Board S Ackland, Australia W T Beck, USA J R Bertino, USA P Borst, The Netherlands P A Bunn, USA C Cass, Canada P Dennis USA P J Houghton, USA M B Kastan, USA S B Kaye, UK
V Ling, Canada H M Pinedo, The Netherlands Y G Pommier, USA I Roninson, USA A Sparreboom, USA B A Teicher, USA K D Tew, USA T Tsuruo, Japan E G E de Vries, The Netherlands C R Wolf, UK
Editorial Board S L Kelly, UK J Kovacs, USA J Rex, UK
D Sanglard, Switzerland T Walsh, USA D Warnock, USA
Editorial Board Alan F Cowman, Australia P J Johnson, USA M Ouellette, Canada
T Wellems, USA N J White, Thailand
Editorial Board D M Coen, USA E D A DeClerq, Belgium F G Hayden, USA D R Kuritzkes, USA
J Montaner, Canada D Richman, USA M A Wainberg, Canada
CONTENTS OF VOLUME 7 Number 1 Editorial
1
Mini reviews Immunotherapy for invasive fungal infections: from bench to bedside Peter G. Pappas
3
Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Rolf Jakobi
11
Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Marion S. Freistadt, Glen D. Meades, Craig E. Cameron
19
Reviews Targeting hypoxia tolerance in cancer Bradly G. Wouters, Twan van den Beucken, Michael G. Magagnin, Philippe Lambin, Costas Koumenis
25
Opportunistic amoebae: challenges in prophylaxis and treatment Frederick L. Schuster, Govinda S. Visvesvara
41
NF-kB in cancer—a friend turned foe Rajani Ravi, Atul Bedi
53
Literature highlights Recent research in infectious disease drug resistance
69
Meetings calendar
75
Number 2 Perspectives New cancer therapeutics: target-specific in, cytotoxics out? Henk J. Broxterman, Nafsika H. Georgopapadakou
79
Minireview HIV resistance to the fusion inhibitor enfuvirtide:mechanisms and clinical implications Michael D. Miller, Daria J. Hazuda
89
Reviews ROS stress in cancer cells and therapeutic implications Helene Pelicano, Dennis Carney, Peng Huang
97
Evolution of the serine b-lactamases: past, present and future Barry G. Hall, Miriam Barlow
111
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Martin E. Eichhorn, Sebastian Strieth, Marc Dellian
125
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Sharmila Shankar, Rakesh K. Srivastava
139
Literature highlights Recent research in infectious disease drug resistance
157
Meetings calendar
159
Number 3 Perspectives The emergence of HIV resistance and new antiretrovirals: are we winning? Mark A. Wainberg
163
Reviews Multifaceted roles of cyclooxygenase-2 in lung cancer Karen Riedl, Kostyantyn Krysan, Mehis Po˜ld, Harnisha Dalwadi, Nathalie Heuze-Vourc’h, Mariam Dohadwala, Ming Liu, Xiaoyan Cui, Robert Figlin, Jenny T. Mao, Robert Strieter, Sherven Sharma, Steven M. Dubinett
169
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance David Andes
185
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases ¨ rgen Venitz, William D. Figg, Alex Sparreboom Milin R. Acharya, Ju
195
Customizing chemotherapy for colon cancer: the potential of gene expression profiling John M. Mariadason, Diego Arango, Leonard H. Augenlicht
209
Literature highlights Recent research in infectious disease drug resistance
219
Meetings calendar
223
Numbers 4–5 Minireview Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Roman P. Wernyj, Patrice J. Morin
227
Reviews Artemisinins: mechanisms of action and potential for resistance Sanjeev Krishna, Anne-Catrin Uhlemann, Richard K. Haynes
233
Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Moulay A. Alaoui-Jamali, Isabelle Dupre´, He Qiang
245
Leishmaniasis: drugs in the clinic, resistance and new developments Marc Ouellette, Jolyne Drummelsmith, Barbara Papadopoulou
257
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Jens M. Teodoridis, Gordon Strathdee, Robert Brown
267
Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Miriam K. Laufer, Christopher V. Plowe
279
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Julia Glade Bender, Erin M. Cooney, Jessica J. Kandel, Darrell J. Yamashiro
289
Candida biofilm resistance Pranab K. Mukherjee, Jyotsna Chandra
301
Literature highlights Literature highlights: recent research in infectious diseases drug resistance
311
Meetings calendar
317
Number 6 Perspective Cancer cell death by programmed necrosis? Piet Borst, Sven Rottenberg
321
Minireview Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Lajos Pusztai, Roman Rouzier, Peter Wagner, W. Fraser Symmans
325
Reviews Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Shazib Pervaiz
333
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Caroline M.M. Van Geelen, Elisabeth G.E. de Vries, Steven de Jong
345
Literature highlights Recent research in infectious disease drug resistance
359
Meetings calendar
367
Volume Contents, Author & Keyword Indices, Volume 7 2004
I
Drug Resistance Updates 7 (2004) VII
AUTHOR INDEX VOLUME 7 Acharya, M.R. 195 Alaoui-Jamali, M.A. 245 Andes, D. 185 Arango, D. 209 Arts, E. 1 Augenlicht, L.H. 209 Barlow, M. 111 Bedi, A. 53 Borst, P. 321 Brown, R. 267 Broxterman, H. 1 Broxterman, H.J. 79 Cameron, C.E. 19 Carney, D. 97 Chandra, J. 301 Cooney, E.M. 289 Cui, X. 169 Dalwadi, H. 169 de Jong, S. 345 de Vries, E.G.E. 345 Dellian, M. 125 Dohadwala, M. 169 Drummelsmith, J. 257 Dubinett, S.M. 169 Dupre´, I. 245
Georgopapadakou, N.H. 79 Glade Bender, J. 289
Po˜ ld, M. 169 Pusztai, L. 325
Hall, B.G. 111 Haynes, R.K. 233 Hazuda, D.J. 89 Heuze-Vourc’h, N. 169 Huang, P. 97
Qiang, H. 245 Ravi, R. 53 Riedl, K. 169 Rottenberg, S. 321 Rouzier, R. 325
Jakobi, R. 11 Kandel, J.J. 289 Koumenis, C. 25 Krishna, S. 233 Krysan, K. 169 Lambin, P. 25 Laufer, M.K. 279 Liu, M. 169 Magagnin, M.G. 25 Mao, J.T. 169 Mariadason, J.M. 209 Meades, G.D. 19 Miller, M.D. 89 Morin, P.J. 227 Mukherjee, P.K. 301
Schuster, F.L. 41 Shankar, S. 139 Sharma, S. 169 Sparreboom, A. 195 Srivastava, R.K. 139 Strathdee, G. 267 Strieter, R. 169 Strieth, S. 125 Symmans, W.F. 325 Teodoridis, J.M. 267 Uhlemann, A.-C. 233 van den Beucken, T. 25 Van Geelen, C.M.M. 345 Venitz, J. 195 Visvesvara, G.S. 41
Ouellette, M. 257 Eichhorn, M.E. 125 Figg, W.D. 195 Figlin, R. 169 Freistadt, M.S. 19 Georgopapadakou, N. 1
Papadopoulou, B. 257 Pappas, P.G. 3 Pelicano, H. 97 Perfect, J. 1 Pervaiz, S. 333 Plowe, C.V. 279
Wagner, P. 325 Wainberg, M.A. 163 Ward, S. 1 Wernyj, R.P. 227 Wouters, B.G. 25 Yamashiro, D.J. 289
Drug Resistance Updates 7 (2004) IX–XV
KEYWORD INDEX VOLUME 7 ABC transporters Leishmaniasis: drugs in the clinic, resistance and new developments Acanthamoeba spp. Opportunistic amoebae: challenges in prophylaxis and treatment Adjuvant chemotherapy Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? AEE788 New cancer therapeutics: target-specific in, cytotoxics out? Alkylating agents Cancer cell death by programmed necrosis? Amoebic encephalitis Opportunistic amoebae: challenges in prophylaxis and treatment Amoebic keratitis Opportunistic amoebae: challenges in prophylaxis and treatment Amphotericin B Leishmaniasis: drugs in the clinic, resistance and new developments Amphotericin pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Angiogenesis Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Angiopoietin Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Anti-angiogenesis Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Anti-angiogenic therapy Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Anticancer agents ROS stress in cancer cells and therapeutic implications Anticancer drugs Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Antifungal PK/PD Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Antifungal therapy Candida biofilm resistance Antiviral agent Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Apoptosis Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis NF-kB in cancer—a friend turned foe ROS stress in cancer cells and therapeutic implications Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Cancer cell death by programmed necrosis? Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Artemisinin Artemisinins: mechanisms of action and potential for resistance Balamuthia mandrillaris Opportunistic amoebae: challenges in prophylaxis and treatment
257 41 325 79 321 41 41 257 185 125 289 125 289 125 97 195 185 301 19 11 53 97 139 321 345 233
41
X
KEYWORD INDEX VOLUME 7
Bevacizumab Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Biofilm Candida biofilm resistance Biomarkers New cancer therapeutics: target-specific in, cytotoxics out? BMS-488043 The emergence of HIV resistance and new antiretrovirals: are we winning? Breast cancer Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Cancer NF-kB in cancer—a friend turned foe ROS stress in cancer cells and therapeutic implications Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Cancer chemoprevention Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Cancer therapy Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Carcinogenesis NF-kB in cancer—a friend turned foe Caspase Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Caspase-activated protein kinases Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Celecoxib Multifaceted roles of cyclooxygenase-2 in lung cancer Chemically modified tetracyclines Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Chloroquine Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies CI-1040 New cancer therapeutics: target-specific in, cytotoxics out? Cisplatin Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel CK2 NF-kB in cancer—a friend turned foe Clinical trial Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Multifaceted roles of cyclooxygenase-2 in lung cancer Colon cancer Customizing chemotherapy for colon cancer: the potential of gene expression profiling Colon carcinoma Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Coxsackievirus B3 Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? CpG-islands Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Cyclooxygenase Multifaceted roles of cyclooxygenase-2 in lung cancer Cytokine growth factors Immunotherapy for invasive fungal infections: from bench to bedside DcR1 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy DcR2 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Death receptor Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
289 301 79 163 325
53 97 245 333 11 53
139 11 169 195 279 79 227 53 125 169 209 345 19 267 169 3
345 345
139
KEYWORD INDEX VOLUME 7
Dihydrofolate reductase Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Dihydropteroate synthase Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies DNMT Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker DR4 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy DR5 Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug development Chemically modified tetracyclines as inhibitors of matrix metalloproteinases Drug resistance Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Drug susceptibility Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Drug-resistant HIV The emergence of HIV resistance and new antiretrovirals: are we winning? Echinocandin pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance Endoperoxides Artemisinins: mechanisms of action and potential for resistance Enfuvirtide HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Entry HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Epigenetics Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Erlotinib New cancer therapeutics: target-specific in, cytotoxics out? Error catastrophe Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Evolutionary potential Evolution of the serine b-lactamases: past, present and future Flavonoids Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Fluconazole Leishmaniasis: drugs in the clinic, resistance and new developments Fluconazole pharmacodynamics Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance 5-FU Customizing chemotherapy for colon cancer: the potential of gene expression profiling Fusion HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Gefitinib New cancer therapeutics: target-specific in, cytotoxics out? Gene expression profiling Customizing chemotherapy for colon cancer: the potential of gene expression profiling Genomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Gleevec New cancer therapeutics: target-specific in, cytotoxics out? Glucantime Leishmaniasis: drugs in the clinic, resistance and new developments Glycolysis Cancer cell death by programmed necrosis?
XI
279 279 267 345 345 195 185 227 245 279 245 163
185 233 89 89 267 79 19 111 333 257 185 209 89
79 209 245 79 257 321
XII
KEYWORD INDEX VOLUME 7
Gp120 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Gp41 HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Granulocyte infusions Immunotherapy for invasive fungal infections: from bench to bedside GW678248 The emergence of HIV resistance and new antiretrovirals: are we winning? GW873140 The emergence of HIV resistance and new antiretrovirals: are we winning? Hepatitis C virus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? HIF Targeting hypoxia tolerance in cancer Histones Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker HIV HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications HIV protease The emergence of HIV resistance and new antiretrovirals: are we winning? Hypoxia Targeting hypoxia tolerance in cancer Hypoxia tolerance Targeting hypoxia tolerance in cancer IAP Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications IKK NF-kB in cancer—a friend turned foe Imatinib New cancer therapeutics: target-specific in, cytotoxics out? Immunotherapy Immunotherapy for invasive fungal infections: from bench to bedside Intensive Care Unit Candida biofilm resistance Invasive fungal infections Immunotherapy for invasive fungal infections: from bench to bedside Iressa New cancer therapeutics: target-specific in, cytotoxics out? Kala azar Leishmaniasis: drugs in the clinic, resistance and new developments b-Lactamases Evolution of the serine b-lactamases: past, present and future Leishmania Leishmaniasis: drugs in the clinic, resistance and new developments Leishmaniasis Leishmaniasis: drugs in the clinic, resistance and new developments Lethal mutagenesis Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Lung cancer Multifaceted roles of cyclooxygenase-2 in lung cancer Malaria Artemisinins: mechanisms of action and potential for resistance Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Matrix metalloproteinase Chemically modified tetracyclines as inhibitors of matrix metalloproteinases
89 89 3 163 163
19 25 267 89 163 25 25
139 53 79 3 301 3 79
257
111 257 257 19 169
233 279 195
KEYWORD INDEX VOLUME 7
Meglumine antimoniate Leishmaniasis: drugs in the clinic, resistance and new developments Methylation Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker Microarray Customizing chemotherapy for colon cancer: the potential of gene expression profiling Miltefosine Leishmaniasis: drugs in the clinic, resistance and new developments Mitochondria ROS stress in cancer cells and therapeutic implications Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Molecular targets Targeting hypoxia tolerance in cancer Mother-to-child transmission The emergence of HIV resistance and new antiretrovirals: are we winning? MUC1 Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel NAD+ Cancer cell death by programmed necrosis? NADP+ Cancer cell death by programmed necrosis? Naegleria fowleri Opportunistic amoebae: challenges in prophylaxis and treatment Necrosis Cancer cell death by programmed necrosis? NF-kB NF-kB in cancer—a friend turned foe NNRTIs The emergence of HIV resistance and new antiretrovirals: are we winning? NRTIs The emergence of HIV resistance and new antiretrovirals: are we winning? PARP Cancer cell death by programmed necrosis? PD0325901 New cancer therapeutics: target-specific in, cytotoxics out? PDGF Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Pentamidine Leishmaniasis: drugs in the clinic, resistance and new developments Pentavalent antimonials Leishmaniasis: drugs in the clinic, resistance and new developments Pentostam Leishmaniasis: drugs in the clinic, resistance and new developments PfCRT Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Pharmacogenomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? (Phospho)proteomics New cancer therapeutics: target-specific in, cytotoxics out? Phylogenies Evolution of the serine b-lactamases: past, present and future Plasmodium falciparum Artemisinins: mechanisms of action and potential for resistance Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Platinum compounds Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Poliovirus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance?
XIII
257 267 209 257 97 139 25 163 227
321 321 41 321 53 163 163
321 79 289 257 257 257 279 245 325 79 111 233 279 227 19
XIV
KEYWORD INDEX VOLUME 7
Predicting evolution Evolution of the serine b-lactamases: past, present and future Predictive markers Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Pro-inflammatory cytokines Immunotherapy for invasive fungal infections: from bench to bedside Protein kinase inhibitors New cancer therapeutics: target-specific in, cytotoxics out? Proteomics Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling Reactive oxygen species (ROS) ROS stress in cancer cells and therapeutic implications Resistance HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications Resistance mechanisms Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel Resveratrol Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol Reverse transcriptase The emergence of HIV resistance and new antiretrovirals: are we winning? Reverset The emergence of HIV resistance and new antiretrovirals: are we winning? Ribavirin Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? RNA virus Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? RNA-dependent RNA polymerase Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Sappinia diploidea Opportunistic amoebae: challenges in prophylaxis and treatment SCH-D The emergence of HIV resistance and new antiretrovirals: are we winning? SPD754 The emergence of HIV resistance and new antiretrovirals: are we winning? Stibogluconate Leishmaniasis: drugs in the clinic, resistance and new developments SU-11248 New cancer therapeutics: target-specific in, cytotoxics out? SU-5416 New cancer therapeutics: target-specific in, cytotoxics out? Subcellular localization Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Sulfadoxine–pyrimethamine Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies Tarceva New cancer therapeutics: target-specific in, cytotoxics out? Target selection New cancer therapeutics: target-specific in, cytotoxics out? Therapy Targeting hypoxia tolerance in cancer TMC114 The emergence of HIV resistance and new antiretrovirals: are we winning? TRAIL Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications TRAIL-resistance Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Translation Targeting hypoxia tolerance in cancer
111 325 3 79 245
97 89 227 333 163 163 19 19 19
41 163 163 257 79 79 11 279
79 79 25 163
139 345 25
KEYWORD INDEX VOLUME 7
Trastuzumab New cancer therapeutics: target-specific in, cytotoxics out? Treatment NF-kB in cancer—a friend turned foe Tumor Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Vascular remodeling Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Vascular targeting Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives VEGF Vascular remodeling and clinical resistance to antiangiogenic cancer therapy Xyotax New cancer therapeutics: target-specific in, cytotoxics out? ZD1839 New cancer therapeutics: target-specific in, cytotoxics out? ZM447439 New cancer therapeutics: target-specific in, cytotoxics out?
XV
79 53 125
289 125 289
79
79 79